Pharma

Taking stock of the drug industry, from the lab to the medicine chest. For a weekly update, sign up for our free Pharmalot newsletter. And subscribe to STAT+ for exclusive coverage and analysis of the pharma industry — from drug pipelines to boardroom shakeups.

Pharmalot Ed Silverman

Pharmalittle: Judge rules Walgreens helped fuel San Francisco opioid crisis; U.S. plan to bottle monkeypox vaccine could take months

Haleon, the consumer health unit recently spun off by GSK, insists it is not a party to U.S. litigation focused on the Zantac heartburn drug.

Read The Story

Pharmalot Ed Silverman

Pharmalittle: Endo bankruptcy filing over opioid crisis appears imminent; U.S. to allow fractional doses of monkeypox vaccine

Pharmalot Ed Silverman

For the second time, Pfizer tries a warranty in response to concerns over high drug costs

Pharmalot Ed Silverman

U.S. appeals court panel decides AbbVie’s ‘patent thickets’ for Humira don’t thwart competition

Special Report Bob Herman, Kate Sheridan, J. Emory Parker, Adam Feuerstein and Mohana Ravindranath

Health care’s high rollers: As the pandemic raged, CEOs’ earnings surged

All Coverage

Pharmalot Ed Silverman

Pharmalittle: Pfizer to test a Lyme disease vaccine; only monkeypox drug in the U.S. is hard to access

Pharmalot Ed Silverman

Pharmalittle: Medicare is poised to negotiate drug prices; Pfizer to pay $5.4 billion for Global Blood Therapeutics

Pharmalot Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

Pharmalittle: PhRMA threatens Dems if drug-pricing bill passes; Novo plays down worries over obesity drug supplies

Pharmalot Ed Silverman

Pharmalittle: U.S. government blunder contributed to monkeypox vax shortage; Amgen to pay $4 billion for ChemoCentryx

Pharmalot Ed Silverman

Lilly is ordered to pay $61 million for shortchanging the Medicaid drug rebate program

Pharmalot Ed Silverman

Civica Rx begins selling its first outpatient generic drug as it tries to overhaul the pharmaceutical supply chain

Pharmalot Ed Silverman

Pharmalittle: AbbVie wins court opinion on Humira patent thickets; Alnylam heart disease drug succeeds in closely watched trial

Pharmalot Ed Silverman

Pharmalittle: West Virginia cities reach deal with wholesalers over opioid crisis; Democrats’ economic plan would raises taxes on pharma

Pharmalot Ed Silverman

Major European research funders often fail to set policies or monitor progress on clinical trial transparency

Pharmalot Ed Silverman

Pharmalittle: Global demand for monkeypox vaccine will be hard to meet; Amgen dispute with IRS heats up

Pharmalot Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

Pharmalittle: Pharma wages ‘hail Mary’ campaign to sink reconciliation bill; Moderna inks $1.74 billion deal with U.S. for Omicron shot

Pharmalot Ed Silverman

A ViiV deal to license its HIV prevention shot to poor countries runs into criticism

Pharmalot Ed Silverman

Pharmalittle: AbbVie’s Allergan reaches $2 billion deal on opioid lawsuits; internal IQVIA documents question patient data privacy

Pharmalot Ed Silverman

AbbVie is scolded by a trade group over sales rep ‘strategically loitering’ in a hospital

Pharmalot Ed Silverman

Wyden says Merck and Abbott aren’t cooperating with probe into pharma tax practices

Pharmalot Ed Silverman

Pharmalittle: Teva reaches $4.25 billion deal over its role in opioid crisis; feds probe Cassava over Alzheimer’s drug data

Pharma Geoff Mulvihill — Associated Press

Drugmaker Teva latest to settle opioid lawsuits nationally

Pharmalot Ed Silverman

FDA’s decision to review a Biogen ALS drug is met with skepticism and uncertainty on Wall Street

Pharmalot Ed Silverman

Pharmalittle: FDA will review Biogen ALS drug despite inconclusive results; Shkreli launches drug-discovery software company

Pharma Nicholas Florko

Despite their anger over high drug prices, Americans are giving pharma credit for helping contain Covid-19

Pharmalot Ed Silverman

‘No magic bullet’: For drugmakers and the FDA, clinical trials on ultra-rare diseases pose thorny challenges

Pharmalot Ed Silverman

Pharma

Pharmalittle: Judge rules Walgreens helped fuel San Francisco opioid crisis; U.S. plan to bottle monkeypox vaccine could take months

Pharmalittle: Endo bankruptcy filing over opioid crisis appears imminent; U.S. to allow fractional doses of monkeypox vaccine

For the second time, Pfizer tries a warranty in response to concerns over high drug costs

U.S. appeals court panel decides AbbVie’s ‘patent thickets’ for Humira don’t thwart competition

Health care’s high rollers: As the pandemic raged, CEOs’ earnings surged

All Coverage

Pharmalittle: Pfizer to test a Lyme disease vaccine; only monkeypox drug in the U.S. is hard to access

Pharmalittle: Medicare is poised to negotiate drug prices; Pfizer to pay $5.4 billion for Global Blood Therapeutics

Up and down the ladder: The latest comings and goings

Pharmalittle: PhRMA threatens Dems if drug-pricing bill passes; Novo plays down worries over obesity drug supplies

Pharmalittle: U.S. government blunder contributed to monkeypox vax shortage; Amgen to pay $4 billion for ChemoCentryx

Lilly is ordered to pay $61 million for shortchanging the Medicaid drug rebate program

Civica Rx begins selling its first outpatient generic drug as it tries to overhaul the pharmaceutical supply chain

Pharmalittle: AbbVie wins court opinion on Humira patent thickets; Alnylam heart disease drug succeeds in closely watched trial

Pharmalittle: West Virginia cities reach deal with wholesalers over opioid crisis; Democrats’ economic plan would raises taxes on pharma

Major European research funders often fail to set policies or monitor progress on clinical trial transparency

Pharmalittle: Global demand for monkeypox vaccine will be hard to meet; Amgen dispute with IRS heats up

Up and down the ladder: The latest comings and goings

Pharmalittle: Pharma wages ‘hail Mary’ campaign to sink reconciliation bill; Moderna inks $1.74 billion deal with U.S. for Omicron shot

A ViiV deal to license its HIV prevention shot to poor countries runs into criticism

Pharmalittle: AbbVie’s Allergan reaches $2 billion deal on opioid lawsuits; internal IQVIA documents question patient data privacy

AbbVie is scolded by a trade group over sales rep ‘strategically loitering’ in a hospital

Wyden says Merck and Abbott aren’t cooperating with probe into pharma tax practices

Pharmalittle: Teva reaches $4.25 billion deal over its role in opioid crisis; feds probe Cassava over Alzheimer’s drug data

Drugmaker Teva latest to settle opioid lawsuits nationally

FDA’s decision to review a Biogen ALS drug is met with skepticism and uncertainty on Wall Street

Pharmalittle: FDA will review Biogen ALS drug despite inconclusive results; Shkreli launches drug-discovery software company

Despite their anger over high drug prices, Americans are giving pharma credit for helping contain Covid-19

‘No magic bullet’: For drugmakers and the FDA, clinical trials on ultra-rare diseases pose thorny challenges

McDonald’s is criticized for leaving antibiotic reduction targets off its menu

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day